This article is more than 5 years old. Information may no longer be current.
Less scarring noted with MPD use after acute pyelonephritis
Huang YY. Pediatrics. 2011;doi:10.1542/peds.2010-0297.
Click Here to Manage Email Alerts
Renal scarring associated with pyelonephritis was far less common among hospitalized children who had been treated with adjunctive oral methylprednisolone sodium phosphate combined with antibiotics, according to a study published online.
Ya-Yun Huang, MD, of the National Cheng Kung University Medical College and Hospital in Tainan, Taiwan, and colleagues examined data on 84 children who were aged 1 week to 16 years, had evidence of urinary tract infection and were at increased risk for renal scar formation.
Nineteen children were administered antibiotics with oral methylprednisolone sodium phosphate (MPF; 1.6 mg/kg per day for 3 days), and the remainder of the children received antibiotics with a placebo (every 6 hours for 3 days). Huang and colleagues then examined results from a follow-up dimercaptosuccinic acid scan 6 months after treatment.
The researchers noted renal scarring in 33.3% of those children who received MPD and 60% of the placebo group.
“Adjunctive oral MPD with adequate antibiotics merits further consideration as a potential treatment regimen to alleviate permanent tissue injury in admitted children with serious acute pyelonephritis,” the researchers concluded.
Disclosure: The researchers report no relevant financial disclosures.
 |
Follow the PediatricSuperSite.com on Twitter. |